Q&A: Bayer oncology head Christine Roth talks strategy under new CEO

Un­der new CEO Bill An­der­son, Bay­er re­mains com­mit­ted to be­com­ing a top 10 on­col­o­gy play­er, and the road to do­ing so will be paved by key part­ner­ships and progress in prostate and gas­troin­testi­nal can­cers, ex­ec­u­tives said Wednes­day.

That could mean “good-sized” ac­qui­si­tions that hit the com­pa­ny’s “sweet spot” of fo­cus, whether it be a par­tic­u­lar modal­i­ty or pa­tient pop­u­la­tion, said Chris­tine Roth, head of Bay­er’s on­col­o­gy strate­gic busi­ness unit, dur­ing an event at the com­pa­ny’s Re­search and In­no­va­tion Cen­ter in Cam­bridge, MA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.